Oral Micronized Progesterone and Sildenafil Interaction: What Clinicians and Patients Need to Know

How These Two Drugs Interact at the Molecular Level

Both oral micronized progesterone and sildenafil are metabolized primarily by cytochrome P450 3A4 (CYP3A4), and both exert vasodilatory effects through distinct but converging pathways. The result is a two-pronged interaction: competitive pharmacokinetic interference at the enzyme level, and additive pharmacodynamic pressure on vascular tone.

CYP3A4 Pharmacokinetics

Oral micronized progesterone is extensively metabolized by CYP3A4 in the intestinal wall and liver during first-pass metabolism, producing metabolites including 5α-dihydroprogesterone and allopregnanolone. The FDA-approved Prometrium prescribing information confirms CYP3A4 as the principal metabolic route. [1]

Sildenafil is similarly cleared by CYP3A4 (major) and CYP2C9 (minor). The FDA label for Viagra states that CYP3A4 inhibitors such as erythromycin raise sildenafil AUC by approximately 182%, illustrating just how sensitive sildenafil exposure is to CYP3A4 flux. [2]

When two CYP3A4 substrates compete for the same enzyme pool, the slower or higher-affinity substrate accumulates. Progesterone has a relatively high intrinsic affinity for CYP3A4. A 2013 in-vitro study published in Drug Metabolism and Disposition found that progesterone acts as a competitive inhibitor of CYP3A4 with a Ki of approximately 5 µM, a concentration achievable at therapeutic oral doses. [3] Elevated sildenafil plasma levels increase both efficacy and adverse-effect risk, including hypotension.

P-Glycoprotein and Intestinal Efflux

Sildenafil is also a P-glycoprotein (P-gp) substrate. Progesterone inhibits P-gp transport in vitro, as demonstrated in Caco-2 cell models. A 2004 paper in the Journal of Pharmacology and Experimental Therapeutics (JPET) confirmed progesterone-mediated P-gp inhibition at concentrations consistent with portal-vein exposure after oral dosing. [4] Reduced P-gp efflux in the gut wall allows more sildenafil to reach the systemic circulation, compounding the CYP3A4 effect.

Pharmacodynamic Convergence on Vascular Tone

Progesterone relaxes vascular smooth muscle through non-genomic membrane receptor signaling and by modulating calcium-channel activity. A review in Steroids (2018) confirmed that natural progesterone produces dose-dependent vasodilation independent of its genomic progestational effects. [5]

Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing degradation of cyclic GMP in vascular smooth muscle and potentiating nitric-oxide-driven vasodilation. The NEJM SUPER-2 trial and the original sildenafil pharmacology data, published in NEJM 1998 (N=532), confirmed mean systolic BP drops of 8 to 10 mmHg at the 100 mg dose. [6]

Two agents that each lower blood pressure through different mechanisms, taken together, produce additive or potentially greater-than-additive drops in BP. This risk is highest within the first 1 to 2 hours after both drugs are absorbed.

Clinical Severity: How Serious Is This Combination?

The interaction is rated moderate-to-significant in major drug-interaction databases including Lexicomp and Drugs.com, though it is not listed as absolutely contraindicated the way sildenafil plus nitrates are. The absence of an absolute contraindication does not mean the combination is low-risk.

Distinguishing "Moderate" From "Minor"

A "moderate" DDI rating means the interaction may worsen a patient's clinical condition and requires active management, not mere awareness. The FDA's guidance on drug interaction studies (2020) defines a moderate interaction as one that alters the AUC or Cmax of a victim drug by 2-fold to 5-fold, or produces a clinically measurable pharmacodynamic change. [7]

For a patient already at risk for orthostatic hypotension, including postmenopausal women on HRT who may also have subclinical cardiovascular disease, even an 8 to 12 mmHg additive systolic drop can trigger symptomatic lightheadedness or a fall.

Who Is at Highest Risk?

Women using Prometrium for HRT endometrial protection who are also prescribed sildenafil for pulmonary arterial hypertension (PAH) represent the highest-risk group. Current AHA/ACC guidelines acknowledge that women comprise the majority of PAH patients and that sildenafil is a first-line therapy. [8] These patients typically take sildenafil three times daily at 20 mg (PAH dosing) or up to 100 mg on-demand, creating sustained plasma levels that overlap consistently with progesterone's twice-daily or nightly dosing.

Additional risk factors include:

• Baseline systolic BP <110 mmHg
• Concomitant antihypertensive use
• Age over 65
• Dehydration or volume depletion
• First dose of sildenafil (tolerance has not yet developed)

Pharmacokinetic Data: What Happens to Drug Levels?

No dedicated pharmacokinetic trial has studied the oral micronized progesterone and sildenafil combination directly. This gap is itself clinically significant. The interaction is inferred from:

1. Shared CYP3A4 metabolism (both drugs confirmed substrates)
2. Progesterone's Ki for CYP3A4 inhibition (~5 µM, achievable at 200 mg oral dose) [3]
3. Sildenafil's established sensitivity to CYP3A4 modulators (182% AUC increase with erythromycin) [2]
4. P-gp inhibition by progesterone in intestinal models [4]

The table below summarizes predicted sildenafil exposure changes based on analogous CYP3A4 interaction data:

| Scenario | Predicted Sildenafil AUC Change | Clinical Implication | |---|---|---| | Sildenafil alone (100 mg) | Baseline | Standard BP drop ~8 to 10 mmHg systolic | | + Weak CYP3A4 inhibitor | +30 to 60% | Mild additional BP reduction | | + Moderate CYP3A4 inhibitor | +100 to 180% | Clinically significant hypotension risk | | Progesterone (estimated category) | +40 to 100% (modeled) | Monitor BP; consider dose reduction |

These estimates are modeled from published CYP3A4 interaction magnitudes, not direct trial data. A clinician should treat this as a "moderate inhibitor" scenario until dedicated PK data exists.

Timing and Tmax Overlap

Oral progesterone taken at bedtime reaches peak plasma concentration (Tmax) at approximately 2 to 3 hours post-dose. The Prometrium prescribing information reports a mean Cmax of 17.03 ng/mL at 3 hours after a single 200 mg dose taken with food. [1]

Sildenafil taken orally peaks at 30 to 120 minutes. If a patient takes sildenafil for PAH at a morning or midday dose and then takes progesterone at 10 PM, there may be limited direct Tmax overlap. If sildenafil is taken on-demand in the evening, both drugs peak within hours of each other and the pharmacodynamic risk is highest.

Monitoring and Clinical Management

Active management, not passive awareness, is required when these drugs are co-prescribed.

Blood Pressure Protocol

Measure seated and standing blood pressure at baseline before starting the combination. Recheck at 1 hour and 2 hours after the first combined dose. A drop of more than 20 mmHg systolic or 10 mmHg diastolic on standing (orthostatic hypotension by standard definition) warrants dose adjustment or schedule separation. The AHA defines orthostatic hypotension as a sustained reduction of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing. [9]

Scheduling to Reduce Overlap

Separate the dosing times by at least 4 to 6 hours when clinically feasible. Prometrium is typically taken at bedtime (which also reduces its sedative side effects from allopregnanolone). Scheduling sildenafil in the morning (for PAH) keeps Tmax windows apart and reduces the period of simultaneous peak plasma concentrations.

Dose Considerations

A sildenafil dose reduction from 100 mg to 25 to 50 mg may be warranted in patients on concomitant progesterone who experience symptomatic hypotension. The Viagra label recommends starting at 25 mg in patients taking CYP3A4 inhibitors such as erythromycin or saquinavir. [2] The same conservative starting strategy applies here.

For PAH dosing (Revatio 20 mg three times daily), dose adjustment is less commonly needed but BP monitoring is still essential.

Labs and Ongoing Follow-Up

No specific laboratory monitoring beyond blood pressure is routinely required. Liver function tests are worth checking at baseline since both drugs are hepatically cleared, and CYP3A4 activity is reduced in liver disease, which amplifies the interaction. NCBI StatPearls notes that sildenafil AUC increases approximately 84% in patients with hepatic impairment, even before adding a CYP3A4 competitor. [10]

Patient Counseling Points

Clear, specific instructions reduce the chance that a patient dismisses mild symptoms until they become dangerous.

What to Tell the Patient

Tell the patient to:

• Sit or lie down for at least 30 minutes after taking either drug for the first time together.
• Rise slowly from a sitting or lying position. Orthostatic hypotension often causes falls.
• Report any dizziness, faintness, sudden headache, or racing heartbeat within 2 hours of taking either drug.
• Avoid alcohol on the same day. Alcohol compounds vasodilation from both agents. The Prometrium label explicitly warns that alcohol may increase the sedative and vasodilatory effects of micronized progesterone. [1]
• Never add a nitrate (nitroglycerin, isosorbide, amyl nitrate) while taking sildenafil. Adding a nitrate to a patient already on sildenafil and progesterone creates a triple vasodilatory burden that may cause catastrophic hypotension.

Sildenafil for Erectile Dysfunction vs. PAH: Different Risk Profiles

Men using sildenafil 50 to 100 mg on-demand for erectile dysfunction and also taking progesterone (which may occur in transgender women on feminizing hormone therapy or in men on specific compounded HRT protocols) face a higher single-dose hypotension risk because ED dosing involves higher milligram amounts per event.

Men or transgender women in this situation should be counseled to take the lowest effective sildenafil dose, time it at least 4 hours away from progesterone, and check their own blood pressure before taking sildenafil if they have a home monitor. CDC data show that nearly 46% of U.S. Adults have hypertension or take antihypertensive medications, meaning many patients on combined regimens will already have altered BP baseline. [11]

Progesterone's Other Significant Drug Interactions: Context for Prescribers

Understanding where sildenafil fits in the broader progesterone interaction spectrum helps prescribers prioritize counseling.

Strong CYP3A4 Inducers

Drugs such as rifampin, carbamazepine, and phenytoin dramatically reduce progesterone plasma levels by inducing CYP3A4 and accelerating progesterone clearance. A pharmacokinetic study published in Clinical Pharmacology and Therapeutics demonstrated that rifampin reduced oral progesterone AUC by approximately 70%. [12] Women relying on progesterone for endometrial protection in HRT may lose efficacy if a CYP3A4 inducer is added.

Strong CYP3A4 Inhibitors

Ketoconazole, itraconazole, and ritonavir substantially raise progesterone levels, increasing both therapeutic and sedative-adverse effects. The Prometrium label specifically warns about concomitant use with CYP3A4 inhibitors. [1] Sildenafil sits in a milder category than these agents, but the directional effect is the same.

Sedative CNS Agents

Progesterone's allopregnanolone metabolite is a positive allosteric modulator of GABA-A receptors, producing sedation. A 2018 study in Psychopharmacology (N=16) confirmed that oral micronized progesterone 200 mg produced measurable sedation on standardized scales within 90 minutes of dosing. [13] Benzodiazepines, zolpidem, and opioids compound this sedation. Sildenafil does not add meaningful CNS sedation but does add hypotension, which can mimic sedation-related falls.

Estrogen Combinations in HRT

Within standard continuous combined HRT regimens, progesterone is used alongside estradiol. Estradiol is also a CYP3A4 substrate and may modestly alter CYP3A4 activity. The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement notes that the interaction profile of combined estrogen-progesterone HRT requires individualized assessment when other CYP3A4-active drugs are added. [14] A patient on estradiol plus Prometrium plus sildenafil carries a three-way CYP3A4 substrate load that warrants extra vigilance.

Regulatory and Guideline Positions

The FDA labels for both Prometrium and Viagra/Revatio contain relevant but general language.

The Prometrium label states: "CYP3A4 may be involved in progesterone metabolism" and advises caution with CYP3A4 inhibitors and inducers but does not enumerate sildenafil specifically. [1]

The Revatio (sildenafil 20 mg) label for PAH carries a contraindication against nitrates and a caution against CYP3A4 inhibitors, noting that "the dose of sildenafil may need to be reduced." The Revatio prescribing information is available on the FDA's accessdata portal. [15]

Neither label names the other drug. This regulatory gap is common in drug-drug interaction labeling. Clinicians must integrate the mechanistic data themselves, which is precisely the purpose of the framework outlined in this article.

The Endocrine Society's 2023 Clinical Practice Guideline on menopause management makes no specific statement on PDE5 inhibitor co-administration, reflecting the general state of the literature. Clinicians can access that guideline through the Endocrine Society's peer-reviewed publication. [16]

Special Populations

Postmenopausal Women With Pulmonary Arterial Hypertension

This is the highest-risk clinical scenario. These patients often have reduced cardiac reserve, baseline elevated pulmonary pressures, and may already experience orthostatic symptoms from PAH itself. The progesterone dose should be reviewed for necessity. If endometrial protection is the goal and a lower-dose or non-oral route is feasible (such as a levonorgestrel intrauterine system for endometrial protection), the systemic pharmacokinetic interaction is eliminated. ACOG Practice Bulletin No. 141 acknowledges that the levonorgestrel IUD is an acceptable alternative for endometrial protection in women who cannot tolerate systemic progestogens. [17]

Transgender Women

Transgender women on feminizing hormone therapy may use oral micronized progesterone (off-label, at doses of 100 to 200 mg nightly) and may also use sildenafil for erectile function if they have not undergone vaginoplasty. The same CYP3A4 and pharmacodynamic interaction applies. The bedtime dosing of progesterone in this context means sildenafil taken in the evening for sexual activity will overlap directly with peak progesterone plasma levels, representing the highest-risk timing scenario.

Hepatic Impairment

Both drugs clear more slowly in hepatic impairment. Sildenafil AUC rises approximately 84% in mild-to-moderate hepatic impairment [10], and progesterone clearance is similarly prolonged. The combination in a patient with Child-Pugh A or B liver disease should be approached with extra caution and, if used, with the lowest possible sildenafil dose (25 mg for ED, or standard 20 mg for PAH with close BP monitoring).